Navigation Links
NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Date:9/27/2007

ANN ARBOR, Mich., Sept. 27 /PRNewswire/ -- The National Institute of Standards and Technology (NIST) has selected Velcura Therapeutics, Inc. as an award winner in the Commerce Department's Advanced Technology Program (ATP), a peer-reviewed competition. NIST announced today that $2 million was awarded to the early-phase Michigan biotechnology company developing drug therapies to treat osteoporosis, bone cancer, bone fractures, and other bone disorders.

Velcura scientists have discovered a family of small molecules that possess characteristics of dual-action therapies, both stimulating bone formation and inhibiting loss. "These molecules are rapidly cleared from the blood stream, so these new drugs offer low systemic exposure, reduced off- target effects and extended time on target resulting in increased efficacy," according to Michael W. Long, PhD, president and CEO of Velcura Therapeutics, Inc. "This makes them effective agents for cancer patients and Velcura will start clinical trials I Multiple Myeloma patients for its first therapy, VEL- 0230, in early 2008."

Velcura's ATP funding supports the development of improved, or second- generation, molecules for use in bone diseases requiring long-term therapy, such rheumatoid arthritis or osteoporosis. "Velcura will use the ATP funding to invent new types of therapeutic molecules that retain the advantages of the current generation of compounds and their dual-action effects," Dr. Long added.

The ATP choose Velcura for its innovative approaches both at the level of medicinal chemistry and in the area of bone cell assay development. Velcura's new therapy could have a major economic impact on the treatment of many bone diseases such as osteoporosis that affects more than 10 million Americans. Current projections indicate a more than $60 billion market worldwide for diagnosis and treatment of the bone disease by 2020.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti-bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com.

About the Advanced Technology Program

Managed by the National Institute of Standards and Technology (NIST), the Advanced Technology Program encourages research on technologies that lead to revolutionary new products and industrial processes and services that address national priorities and generate large societal benefits. Winners are chosen on scientific and technological merit and potential for broad-based economic benefits. A single company can receive up to a total of $2 million for research and development activities for up to three years. Information on the 2007 Advanced Technology Program competition is available at http://www.atp.nist.gov/ and http://www.nist.gov/public_affairs/releases/atp_2007_awards.html. Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
8. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
9. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
10. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
11. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):